A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
© 2022. The Author(s)..
The strikingly high transmissibility and antibody evasion of SARS-CoV-2 Omicron variants have posed great challenges to the efficacy of current vaccines and antibody immunotherapy. Here, we screen 34 BNT162b2-vaccinees and isolate a public broadly neutralizing antibody ZCB11 derived from the IGHV1-58 family. ZCB11 targets viral receptor-binding domain specifically and neutralizes all SARS-CoV-2 variants of concern, especially with great potency against authentic Omicron and Delta variants. Pseudovirus-based mapping of 57 naturally occurred spike mutations or deletions reveals that S371L results in 11-fold neutralization resistance, but it is rescued by compensating mutations in Omicron variants. Cryo-EM analysis demonstrates that ZCB11 heavy chain predominantly interacts with Omicron spike trimer with receptor-binding domain in up conformation blocking ACE2 binding. In addition, prophylactic or therapeutic ZCB11 administration protects lung infection against Omicron viral challenge in golden Syrian hamsters. These results suggest that vaccine-induced ZCB11 is a promising broadly neutralizing antibody for biomedical interventions against pandemic SARS-CoV-2.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Nature communications - 13(2022), 1 vom: 23. Juni, Seite 3589 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhou, Biao [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Viral |
---|
Anmerkungen: |
Date Completed 27.06.2022 Date Revised 01.08.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41467-022-31259-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM342602012 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM342602012 | ||
003 | DE-627 | ||
005 | 20231226014507.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41467-022-31259-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1141.xml |
035 | |a (DE-627)NLM342602012 | ||
035 | |a (NLM)35739114 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhou, Biao |e verfasserin |4 aut | |
245 | 1 | 2 | |a A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.06.2022 | ||
500 | |a Date Revised 01.08.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a The strikingly high transmissibility and antibody evasion of SARS-CoV-2 Omicron variants have posed great challenges to the efficacy of current vaccines and antibody immunotherapy. Here, we screen 34 BNT162b2-vaccinees and isolate a public broadly neutralizing antibody ZCB11 derived from the IGHV1-58 family. ZCB11 targets viral receptor-binding domain specifically and neutralizes all SARS-CoV-2 variants of concern, especially with great potency against authentic Omicron and Delta variants. Pseudovirus-based mapping of 57 naturally occurred spike mutations or deletions reveals that S371L results in 11-fold neutralization resistance, but it is rescued by compensating mutations in Omicron variants. Cryo-EM analysis demonstrates that ZCB11 heavy chain predominantly interacts with Omicron spike trimer with receptor-binding domain in up conformation blocking ACE2 binding. In addition, prophylactic or therapeutic ZCB11 administration protects lung infection against Omicron viral challenge in golden Syrian hamsters. These results suggest that vaccine-induced ZCB11 is a promising broadly neutralizing antibody for biomedical interventions against pandemic SARS-CoV-2 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
650 | 7 | |a BNT162 Vaccine |2 NLM | |
650 | 7 | |a N38TVC63NU |2 NLM | |
700 | 1 | |a Zhou, Runhong |e verfasserin |4 aut | |
700 | 1 | |a Tang, Bingjie |e verfasserin |4 aut | |
700 | 1 | |a Chan, Jasper Fuk-Woo |e verfasserin |4 aut | |
700 | 1 | |a Luo, Mengxiao |e verfasserin |4 aut | |
700 | 1 | |a Peng, Qiaoli |e verfasserin |4 aut | |
700 | 1 | |a Yuan, Shuofeng |e verfasserin |4 aut | |
700 | 1 | |a Liu, Hang |e verfasserin |4 aut | |
700 | 1 | |a Mok, Bobo Wing-Yee |e verfasserin |4 aut | |
700 | 1 | |a Chen, Bohao |e verfasserin |4 aut | |
700 | 1 | |a Wang, Pui |e verfasserin |4 aut | |
700 | 1 | |a Poon, Vincent Kwok-Man |e verfasserin |4 aut | |
700 | 1 | |a Chu, Hin |e verfasserin |4 aut | |
700 | 1 | |a Chan, Chris Chung-Sing |e verfasserin |4 aut | |
700 | 1 | |a Tsang, Jessica Oi-Ling |e verfasserin |4 aut | |
700 | 1 | |a Chan, Chris Chun-Yiu |e verfasserin |4 aut | |
700 | 1 | |a Au, Ka-Kit |e verfasserin |4 aut | |
700 | 1 | |a Man, Hiu-On |e verfasserin |4 aut | |
700 | 1 | |a Lu, Lu |e verfasserin |4 aut | |
700 | 1 | |a To, Kelvin Kai-Wang |e verfasserin |4 aut | |
700 | 1 | |a Chen, Honglin |e verfasserin |4 aut | |
700 | 1 | |a Yuen, Kwok-Yung |e verfasserin |4 aut | |
700 | 1 | |a Dang, Shangyu |e verfasserin |4 aut | |
700 | 1 | |a Chen, Zhiwei |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 13(2022), 1 vom: 23. Juni, Seite 3589 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:23 |g month:06 |g pages:3589 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-022-31259-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2022 |e 1 |b 23 |c 06 |h 3589 |